These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 8613929)

  • 1. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile.
    Caille D; Bergis OE; Fankhauser C; Gardes A; Adam R; Charieras T; Grosset A; Rovei V; Jarreau FX
    J Pharmacol Exp Ther; 1996 Apr; 277(1):265-77. PubMed ID: 8613929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo characterization of T-794, a novel reversible inhibitor of monoamine oxidase-A, as an antidepressant with a wide safety margin.
    Kato M; Katayama T; Iwata H; Yamamura M; Matsuoka Y; Narita H
    J Pharmacol Exp Ther; 1998 Mar; 284(3):983-90. PubMed ID: 9495858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive performance in elderly subjects after a single dose of befloxatone, a new reversible selective monoamine oxidase A inhibitor.
    Rosenzweig P; Patat A; Zieleniuk I; Cimarosti I; Allain H; Gandon JM
    Clin Pharmacol Ther; 1998 Aug; 64(2):211-22. PubMed ID: 9728902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
    Da Prada M; Keller HH; Kettler R
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
    Burkard WP; Bonetti EP; Da Prada M; Martin JR; Polc P; Schaffner R; Scherschlicht R; Hefti F; Müller RK; Wyss PC
    J Pharmacol Exp Ther; 1989 Jan; 248(1):391-9. PubMed ID: 2913284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical pharmacology of befloxatone (MD370503), a new potent reversible MAO-A inhibitor.
    Rovei V; Caille D; Curet O; Ego D; Jarreau FX
    J Neural Transm Suppl; 1994; 41():339-47. PubMed ID: 7931248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A behavioral and neurochemical study on the mechanism of the anxiolytic effect of monoamine oxidase inhibitors].
    Maki Y
    Hokkaido Igaku Zasshi; 2001 May; 76(3):133-42. PubMed ID: 11481866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical profile of befloxatone, a new reversible MAO-A inhibitor.
    Curet O; Damoiseau-Ovens G; Sauvage C; Sontag N; Avenet P; Depoortere H; Caille D; Bergis O; Scatton B
    J Affect Disord; 1998 Dec; 51(3):287-303. PubMed ID: 10333983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral effects and general pharmacology of 4-(5-chloro-benzofuranyl-2)-1-methylpiperidine HC1, an antidepressant inhibiting both monoamine oxidase A and 5-hydroxytryptamine uptake.
    Ortmann R; Radeke E; Buech O; Sigg K; Rogg H; Glatt A; Truog A; Jaekel J; Everitt BJ; Delini-Stula A
    Arzneimittelforschung; 1986 Dec; 36(12):1727-32. PubMed ID: 3566833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E2011 a novel, selective and reversible inhibitor of monoamine oxidase type A.
    Kagaya T; Kajiwara A; Nagato S; Akasaka K; Kubota A
    J Pharmacol Exp Ther; 1996 Jul; 278(1):243-51. PubMed ID: 8764357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile.
    Curet O; Damoiseau G; Aubin N; Sontag N; Rovei V; Jarreau FX
    J Pharmacol Exp Ther; 1996 Apr; 277(1):253-64. PubMed ID: 8613928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB; Weinstock M
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
    Lavian G; Finberg JP; Youdim MB
    Clin Neuropharmacol; 1993; 16 Suppl 2():S1-7. PubMed ID: 8313392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the mechanism of antidepressant-like action of berberine chloride.
    Kulkarni SK; Dhir A
    Eur J Pharmacol; 2008 Jul; 589(1-3):163-72. PubMed ID: 18585703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropsychopharmacological profile in rodents of SR 57746A, a new, potent 5-HT1A receptor agonist.
    Simiand J; Keane PE; Barnouin MC; Keane M; Soubrié P; Le Fur G
    Fundam Clin Pharmacol; 1993; 7(8):413-27. PubMed ID: 7904976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-clinical pharmacology of moclobemide. A review of published studies.
    Burkard WP; Da Prada M; Keller HH; Kettler R; Haefely W
    Br J Psychiatry Suppl; 1989 Oct; (6):84-8. PubMed ID: 2695131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral effects of the beta3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs?
    Consoli D; Leggio GM; Mazzola C; Micale V; Drago F
    Eur J Pharmacol; 2007 Nov; 573(1-3):139-47. PubMed ID: 17669397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of some 1,3,5-trisubstitued-2-pyrazoline derivatives on depression and anxiety parameters of mice.
    Can OD; Ozkay UD; Kaplancikli ZA; Oztürk Y
    Arch Pharm Res; 2009 Sep; 32(9):1293-9. PubMed ID: 19784586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity.
    Dawson LA; Hughes ZA; Starr KR; Storey JD; Bettelini L; Bacchi F; Arban R; Poffe A; Melotto S; Hagan JJ; Price GW
    Neuropharmacology; 2006 Jun; 50(8):975-83. PubMed ID: 16581092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.